<VariationArchive VariationID="2920876" VariationName="NM_033380.3(COL4A5):c.2902dup (p.Glu968fs)" VariationType="Duplication" Accession="VCV002920876" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-29" DateCreated="2024-02-20" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="3081338" VariationID="2920876">
      <GeneList>
        <Gene Symbol="COL4A5" FullName="collagen type IV alpha 5 chain" GeneID="1287" HGNC_ID="HGNC:2207" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="108439838" stop="108697545" display_start="108439838" display_stop="108697545" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="107683073" stop="107940774" display_start="107683073" display_stop="107940774" Strand="+" />
          </Location>
          <OMIM>303630</OMIM>
          <Haploinsufficiency last_evaluated="2020-09-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL4A5">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-09-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL4A5">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_033380.3(COL4A5):c.2902dup (p.Glu968fs)</Name>
      <CanonicalSPDI>NC_000023.11:108622805:GGGGG:GGGGGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>Xq22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="108622805" stop="108622806" display_start="108622805" display_stop="108622806" variantLength="1" positionVCF="108622805" referenceAlleleVCF="A" alternateAlleleVCF="AG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="107866035" stop="107866036" display_start="107866035" display_stop="107866036" variantLength="1" positionVCF="107866035" referenceAlleleVCF="A" alternateAlleleVCF="AG" />
      </Location>
      <ProteinChange>E968fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_232" sequenceAccession="LRG_232">
            <Expression>LRG_232:g.187887dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_232t1" sequenceAccession="LRG_232t1">
            <Expression>LRG_232t1:c.2902dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_232p1" sequenceAccession="LRG_232p1" change="p.Glu968fs">
            <Expression>LRG_232p1:p.Glu968fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_232t2" sequenceAccession="LRG_232t2">
            <Expression>LRG_232t2:c.2902dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_232p2" sequenceAccession="LRG_232p2" change="p.Glu968fs">
            <Expression>LRG_232p2:p.Glu968fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.107866040dup" Assembly="GRCh37">
            <Expression>NC_000023.10:g.107866040dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.108622810dup" Assembly="GRCh38">
            <Expression>NC_000023.11:g.108622810dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011977.2" sequenceAccession="NG_011977" sequenceVersion="2" change="g.187887dup">
            <Expression>NG_011977.2:g.187887dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000495.5" sequenceAccession="NM_000495" sequenceVersion="5" change="c.2902dup">
            <Expression>NM_000495.5:c.2902dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000486.1" sequenceAccession="NP_000486" sequenceVersion="1" change="p.Glu968fs">
            <Expression>NP_000486.1:p.Glu968fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_033380.3" sequenceAccession="NM_033380" sequenceVersion="3" change="c.2902dup" MANESelect="true">
            <Expression>NM_033380.3:c.2902dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_203699.1" sequenceAccession="NP_203699" sequenceVersion="1" change="p.Glu968fs">
            <Expression>NP_203699.1:p.Glu968fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_033380.3(COL4A5):c.2902dup (p.Glu968fs) AND X-linked Alport syndrome" Accession="RCV003622413" Version="1">
        <ClassifiedConditionList TraitSetID="2968">
          <ClassifiedCondition DB="MedGen" ID="C4746986">X-linked Alport syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-03-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-03-06" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-02-20" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="2968" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="220" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Alport syndrome 1, X-linked recessive</ElementValue>
                <XRef ID="Alport+Syndrome/335" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alport Syndrome and Thin Basement Membrane Nephropathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">NEPHROPATHY AND DEAFNESS, X-LINKED</ElementValue>
                <XRef Type="MIM" ID="301050" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">X-linked Alport syndrome</ElementValue>
                <XRef ID="MONDO:0010520" DB="MONDO" />
                <XRef ID="88917" DB="Orphanet" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">XLAS</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATS</ElementValue>
                <XRef ID="GTR000525320" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="301050" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">ATS1</ElementValue>
                <XRef Type="MIM" ID="301050" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5785" />
                <XRef ID="5785" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">In Alport syndrome (AS) a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities to isolated hematuria with a non-progressive or very slowly progressive course is observed. Approximately two thirds of AS is X-linked (XLAS); approximately 15% is autosomal recessive (ARAS), and approximately 20% is autosomal dominant (ADAS). In the absence of treatment, renal disease progresses from microscopic hematuria (microhematuria) to proteinuria, progressive renal insufficiency, and end-stage renal disease (ESRD) in all males with XLAS, and in all males and females with ARAS. Progressive sensorineural hearing loss (SNHL) is usually present by late childhood or early adolescence. Ocular findings include anterior lenticonus (which is virtually pathognomonic), maculopathy (whitish or yellowish flecks or granulations in the perimacular region), corneal endothelial vesicles (posterior polymorphous dystrophy), and recurrent corneal erosion. In individuals with ADAS, ESRD is frequently delayed until later adulthood, SNHL is relatively late in onset, and ocular involvement is rare.</Attribute>
                <XRef ID="NBK1207" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16774" />
                <XRef ID="16774" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">COL4A5-Related Nephropathy</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301386</ID>
                <ID Source="BookShelf">NBK1207</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2002">
                <ID Source="pmc">3110944</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGentest, 2011">
                <ID Source="PubMed">22166944</ID>
              </Citation>
              <XRef ID="63" DB="Orphanet" />
              <XRef ID="88917" DB="Orphanet" />
              <XRef ID="C4746986" DB="MedGen" />
              <XRef ID="MONDO:0010520" DB="MONDO" />
              <XRef Type="MIM" ID="301050" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8352430" SubmissionDate="2024-01-24" DateLastUpdated="2024-02-20" DateCreated="2024-02-20">
        <ClinVarSubmissionID localKey="3669813|OMIM:301050" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004564414" DateUpdated="2024-02-20" DateCreated="2024-02-20" Type="SCV" Version="1" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" OrgAbbreviation="ARUP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-03-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The COL4A5 c.2902dup; p.Glu968GlyfsTer43 variant is reported in the literature in one family affected with X-linked Alport syndrome (Yamamura 2017). This variant is absent from the Genome Aggregation Database, indicating it is not a common polymorphism. This variant causes a frameshift by inserting a single nucleotide, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Variants that create or remove a glycine in Gly-X-Y domains are often deleterious due to glycine repeats (Persikov 2004, Weerakkody 2016). Based on the available information, this variant is considered to be pathogenic. References: Persikov AV et al. Stability related bias in residues replacing glycines within the collagen triple helix (Gly-Xaa-Yaa) in inherited connective tissue disorders. Hum Mutat. 2004 Oct;24(4):330-7. PMID: 15365990. Weerakkody RA et al. Targeted next-generation sequencing makes new molecular diagnoses and expands genotype-phenotype relationship in Ehlers-Danlos syndrome. Genet Med. 2016 Nov;18(11):1119-1127. PMID: 27011056. Yamamura T et al. Natural History and Genotype-Phenotype Correlation in Female X-Linked Alport Syndrome. Kidney Int Rep. 2017 May 4;2(5):850-855. PMID: 29270492.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2024</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/xwiqgyug/arup_molecular_germline_variant_investigation_process_arup-info-0022_2024.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL4A5" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.107866040dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="301050" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2023 ARUP ClinVar submission</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8352430" TraitType="Disease" MappingType="XRef" MappingValue="301050" MappingRef="OMIM">
        <MedGen CUI="C4746986" Name="X-linked Alport syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

